Be part of the knowledge.™

Global Oncology Academy

The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.

For more information about GOA, visit www.globaloncologyacademy.org.

873

LikeLikedUnlike

136-150 of 294

Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Project Oncology®
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
- Namrata Vijayvergia, MD
  Peer
Diagnosing LCNEC of the Lung: Challenges and Strategies
Project Oncology®
Diagnosing LCNEC of the Lung: Challenges and Strategies
- Junaid Arshad, MD, MS
  Peer
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Project Oncology®
Personalizing Care for Large Cell Neuroendocrine Carcinoma
- Junaid Arshad, MD, MS
  Peer
From Trials to Real-World Impact: CAR T-Cell Therapy for R/R Large B-Cell Lymphoma
Project Oncology®
From Trials to Real-World Impact: CAR T-Cell Therapy for R/R Large B-Cell Lymphoma
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Matthew Matasar, MD
  Peer
Analyzing Toxicity Trends Post-CAR T-Cell Therapy: Implications for Patient Monitoring
Project Oncology®
Analyzing Toxicity Trends Post-CAR T-Cell Therapy: Implications for Patient Monitoring
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Manali Kamdar, MD
  Peer
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
advertisement
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Project Oncology®
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
- Aline Fares, MD
  Peer
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Project Oncology®
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
- Ryan Quigley
  Peer
- David F. McDermott, MD
  Peer
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Project Oncology®
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
- Jorge Nieva, MD
  Peer
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Project Oncology®
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
On the Frontlines of Prostate Cancer
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
- Wayne Kuang, MD
  Peer
- William Oh, MD
  Peer
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
On the Frontlines of Prostate Cancer
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
- William Oh, MD
  Peer
advertisement
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Project Oncology®
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
- Jorge Nieva, MD
  Peer
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Project Oncology®
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Project Oncology®
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer

Program Chapters

Segment Chapters

Playlist:

Recommended